Mersana Therapeutics (MRSN) Receives Daily Media Impact Score of 0.01
Press coverage about Mersana Therapeutics (NASDAQ:MRSN) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mersana Therapeutics earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.2426561730816 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Mersana Therapeutics Inc. (MRSN) Expected to Announce Quarterly Sales of $3.36 Million (americanbankingnews.com)
- Mersana Therapeutics (MRSN) PT Set at $33.00 by HC Wainwright (americanbankingnews.com)
- -$0.61 EPS Expected for Mersana Therapeutics Inc. (MRSN) This Quarter (americanbankingnews.com)
- Wired News – European Medicines Agency Granted Orphan Drug Designation for Abeona’s ABO-202 Gene Therapy Program in Batten Disease (finance.yahoo.com)
- Wired News – Krystal Biotech’s Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe (finance.yahoo.com)
Several research firms have commented on MRSN. Leerink Swann reaffirmed an “outperform” rating on shares of Mersana Therapeutics in a research note on Wednesday, March 28th. HC Wainwright began coverage on shares of Mersana Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating for the company. Zacks Investment Research raised shares of Mersana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 18th. Cowen reaffirmed a “buy” rating on shares of Mersana Therapeutics in a research note on Monday, April 16th. Finally, ValuEngine raised shares of Mersana Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $24.80.
Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Wednesday, March 28th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.13). The firm had revenue of $3.26 million during the quarter, compared to analyst estimates of $4.22 million. equities research analysts predict that Mersana Therapeutics will post -2.53 EPS for the current year.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.